3 terminated, 1 completed. 3 Phase 2, 2 Phase 1.
By phase and status
Follow robatumumab: new trials by email Literature Review of robatumumab trials Research Report on robatumumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
Temozolomide, Vincristine, Ifosfamide - Neoplasms, Solid Tumors | Phase 1 | Terminated | 4 | 2009-11-11 | 2018-08-27 |
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
Carboplatin, Epirubicin, Trastuzumab - Neoplasms | Phase 1 / Phase 2 | Terminated | 15 | 2009-09-25 | 2018-08-24 |
A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)
robatumumab - Osteosarcoma, Sarcoma, Ewing's | Phase 2 | Terminated | 219 | 2008-02-01 | 2018-08-23 |
A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)
Robatumumab, Irinotecan, Cetuximab - Colorectal Cancer | Phase 2 | Completed | 67 | 2007-11-21 | 2018-08-24 |
Conditions studied
Neoplasms (2) · Bone Neoplasms (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Neuroblastoma (1) · Neuroectodermal Tumors, Primitive, Peripheral (1) · Osteosarcoma (1) · Sarcoma, Ewing (1)
Sponsors
Merck Sharp & Dohme LLC (4)
Results publications
PMID 22682017, PMID 24905030, PMID 27362300
NIH funding
2009 (1)